{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:56:23Z","timestamp":1793735783635,"version":"4.6.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,20]],"date-time":"2016-02-20T00:00:00Z","timestamp":1455926400000},"content-version":"vor","delay-in-days":780,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.ihj.2013.10.001","type":"journal-article","created":{"date-parts":[[2013,11,6]],"date-time":"2013-11-06T16:31:19Z","timestamp":1383755479000},"page":"16-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4073-4960","authenticated-orcid":false,"given":"Sudhir S.","family":"Shetkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivasubramanian","family":"Ramakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Seth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5655-0277","authenticated-orcid":false,"given":"Puneet","family":"Chandna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil K.","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balram","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay K.","family":"Bahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ihj.2013.10.001_bib1","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1161\/CIRCULATIONAHA.109.192663","volume":"120","author":"Kushner","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2013.10.001_bib2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIR.0b013e318256f1e0","volume":"126","author":"Jneid","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2013.10.001_bib3","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1161\/CIR.0b013e31823a5596","article-title":"2011 ACCF\/AHA\/SCAI guideline for PCI: executive summary: a report of the ACCF\/AHA Task Force on Practice Guidelines and the SCAI","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2013.10.001_bib4","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2013.10.001_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.thromres.2009.01.014","article-title":"Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome","volume":"124","author":"Dupont","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.ihj.2013.10.001_bib6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.thromres.2006.08.012","article-title":"Clopidogrel resistance?","volume":"120","author":"Gurbel","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.ihj.2013.10.001_bib7","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pre-treatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2013.10.001_bib8","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1055\/s-0037-1613462","article-title":"Prevalence of Clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement","volume":"89","author":"Muller","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ihj.2013.10.001_bib9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/dmd.109.029132","article-title":"Identification of the human cytochrome p450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite","volume":"38","author":"Kazui","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ihj.2013.10.001_bib10","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/clpt.2011.132","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines\u00a0for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy","volume":"90","author":"Scott","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ihj.2013.10.001_bib11","first-page":"1","article-title":"The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y12 inhibitors","volume":"12","author":"Price","year":"2011","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.ihj.2013.10.001_bib12","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome P-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2013.10.001_bib13","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ihj.2013.10.001_bib14","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1001\/jama.2010.1566","article-title":"Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle","volume":"304","author":"Fuster","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ihj.2013.10.001_bib15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.thromres.2010.10.021","article-title":"The cytochrome 2C19*2\u00a0and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention","volume":"127","author":"Hwang","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.ihj.2013.10.001_bib16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"CYP 450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2013.10.001_bib17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2013.10.001_bib18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2010.05.013","article-title":"ACCF\/AHA clopidogrel clinical alert: approaches to the FDA \u201cBoxed Warning\u201d","volume":"56","author":"Holmes","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2013.10.001_bib19","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2217\/pgs.09.172","article-title":"Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry","volume":"11","author":"Falzoi","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ihj.2013.10.001_bib20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1373\/clinchem.2006.074856","article-title":"MALDI-TOF mass spectrometry for multiplex genotyping of CYP2B6 single-nucleotide polymorphisms","volume":"53","author":"Blievernicht","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.ihj.2013.10.001_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-385855-9.00001-1","article-title":"Use of matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry for multiplex genotyping","volume":"53","author":"Meyer","year":"2011","journal-title":"Adv Clin Chem"},{"key":"10.1016\/j.ihj.2013.10.001_bib22","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1373\/clinchem.2006.080739","article-title":"Multiplex genotyping of cytochrome p450 single-nucleotide polymorphisms by use of MALDI\u2013TOF mass spectrometry","volume":"53","author":"Misra","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.ihj.2013.10.001_bib23","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ihj.2013.10.001_bib24","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1253\/circj.CJ-09-0019","article-title":"Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in\u00a0an actual clinical setting in Japan","volume":"73","author":"Jinnai","year":"2009","journal-title":"Circ J"},{"key":"10.1016\/j.ihj.2013.10.001_bib25","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jcin.2008.09.008","article-title":"The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial","volume":"1","author":"Gladding","year":"2008","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ihj.2013.10.001_bib26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1365-2125.2003.01883.x","article-title":"Allele and genotype frequency of CYP2C19 in a Tamilian population","volume":"56","author":"Adithan","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ihj.2013.10.001_bib27","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ihj.2013.02.012","article-title":"Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: effects on clopidogrel response","volume":"65","author":"Shalia","year":"2013","journal-title":"Indian Heart J"},{"key":"10.1016\/j.ihj.2013.10.001_bib28","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2217\/pgs.12.24","article-title":"CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects","volume":"13","author":"Chan","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ihj.2013.10.001_bib29","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1008410","article-title":"Effects of CYP2C19 genotype on outcomes of clopidogrel treatment","volume":"363","author":"Par\u00e9","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ihj.2013.10.001_bib30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/hrt.2011.227652","article-title":"Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel","volume":"98","author":"Zabalza","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.ihj.2013.10.001_bib31","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00228-012-1381-8","article-title":"Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population","volume":"69","author":"Subraja","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ihj.2013.10.001_bib32","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.CIR.0000085073.69189.88","article-title":"Adenosine diphosphate induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects","volume":"108","author":"Fontana","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2013.10.001_bib33","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1253\/circj.72.1165","article-title":"Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel","volume":"72","author":"Malek","year":"2008","journal-title":"Circ J"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483213003209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483213003209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T23:06:05Z","timestamp":1564614365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019483213003209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0019483213003209"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2013.10.001","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2013.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Cardiological Society of India. Published by Elsevier, a division of Reed Elsevier India, Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}